Join the club for FREE to access the whole archive and other member benefits.

Calico and AbbVie announced early-stage trials for new therapies

Clinical trials in progress for potential targets of cancer and neurodegenerative diseases


Key points from article :

Calico and AbbVie announced clinical-stage programs in immuno-oncology and neurodegeneration, currently in Phase I studies.

More than 20 active programs in discovery or preclinical development in age-related diseases.

Calico immuno-oncology program is focused on PTPN2 inhibitors.

ABBV-CLS-579 and ABBV-CLS-484 are novel, orally bioavailable PTPN2 inhibitors.

Developed by Calico in collaboration with AbbVie and the Broad Institute of MIT and Harvard.

Lead Calico neurodegeneration molecule (ABBV-CLS-7262) targets stress response pathway.

Therapeutic potential in neurodegenerative diseases, such as ALS, Parkinson’s disease and traumatic brain injury.

Plans to begin a study later this year in patients with ALS.

ABBV-CLS-7262 is licensed from the lab of Peter Walter, Professor of Biochemistry and Biophysics.

"These are early days, but we are looking forward to potential proof-of-concept data from both programs," - Arthur D. Levinson, Founder and CEO of Calico.

Mentioned in this article:

Click on resource name for more details.


Pharmaceutical research and development.

Arthur D. Levinson

CEO of Calico, Chairman of Apple Inc. and former CEO and chairman of Genentech.

Broad Institute of MIT and Harvard

Collaborative organization that brings academics of various disciplines in the scientific community together


Combating aging and associated diseases. An Alphabet (Google) subsidiary.

Peter Walter

Professor at UCSF, investigator at Howard Hughes Medical Institute and Director of Bay Area Institute of Science, Altos Labs

Topics mentioned on this page:
Cancer, Mental Health